X2.2.1 Inhaled bronchodilators for treatment of exacerbations
Inhaled bronchodilators are effective treatments for acute exacerbations (Global Initiative for Chronic Obstructive Lung Disease 2016, Siafakas 1995, American Thoracic Society 1995, British Thoracic Society 1997, Moayyedi 1995, Fernandez 1994) [evidence level I]
In exacerbations of COPD, the immediate bronchodilator effect is small, but may result in significant improvement in clinical symptoms in patients with severe obstruction.
Studies of acute airflow limitation in asthma indicate that beta-agonists are as effectively delivered by metered dose inhaler and spacer as by nebuliser (Cates 2006). The applicability of this evidence to patients with COPD is unknown. There is evidence in patients with a COPD exacerbation that a dry powder inhaler delivering eformoterol is as effective in improving lung function as a metered dose inhaler delivering salbutamol, with or without a spacer device (Selroos 2009) [evidence level II]. An adequate dose should be used. The dose equivalent to 5 mg of salbutamol delivered by nebuliser is 8–10 puffs of 100mcg salbutamol by metered dose inhaler and spacer. Limited evidence indicates dry powder inhalers are as effective as other delivery devices for the administration of short-acting bronchodilators in the setting of acute exacerbations of COPD (Selroos 2009) [evidence level II]. Airflow in the nebuliser should be 6 L per minute or higher to achieve an appropriate aerosol, but using high- flow oxygen should be avoided as this may worsen carbon dioxide retention. High doses of beta-agonists may induce hypokalaemia and predispose to cardiac arrhythmias.
A small (n=30) single centre pilot randomised controlled trial performed in New Zealand (Mukerji 2015) showed that 2g IV magnesium when added to standard bronchodilator therapy in AECOPD significantly improved FEV1 at 120 mins (mean percentage change in FEV1 was 27.07% with magnesium versus 11.39% in the placebo group, 95%CI 3.7 to 27.7, p=0.01). Asthma was excluded on clinical grounds on review of past spirometry. Larger trials with meaningful clinical endpoints are required before this can be recommended as standard therapy.< Prev Next >